Freestone Grove Partners LP Novavax Inc Transaction History
Freestone Grove Partners LP
- $9.71 Trillion
- Q1 2025
A detailed history of Freestone Grove Partners LP transactions in Novavax Inc stock. As of the latest transaction made, Freestone Grove Partners LP holds 14,091 shares of NVAX stock, worth $104,414. This represents 0.0% of its overall portfolio holdings.
Number of Shares
14,091
Previous 48,681
71.05%
Holding current value
$104,414
Previous $391 Million
76.92%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding NVAX
# of Institutions
299Shares Held
90MCall Options Held
5.76MPut Options Held
6.65M-
Vanguard Group Inc Valley Forge, PA15.7MShares$116 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11.8MShares$87.8 Million0.0% of portfolio
-
Shah Capital Management11.1MShares$82.5 Million33.15% of portfolio
-
State Street Corp Boston, MA7.04MShares$52.2 Million0.0% of portfolio
-
Coatue Management LLC New York, NY3.84MShares$28.4 Million0.13% of portfolio
About NOVAVAX INC
- Ticker NVAX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,215,104
- Market Cap $580M
- Description
- Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...